References 1.Mller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschp MH
Ozempic injection is approved to: help manage type 2 diabetes in adults lower the risk of serious heart problems in adults who have type 2 diabetes and heart disease lower the risk of worsening kidney disease and death from cardiovascular (heart or blood vessel) disease in adults who have type 2 diabetes and chronic (long-term) kidney disease However, doctors may also prescribe Ozempic off-label for weight loss in: adults and children ages 12 years and older with obesity adults with overweight and at least one weight-related condition, such as high blood pressure or high cholesterol To find out whether Ozempic may be right for you, talk with your doctor
Two Phase 2 trials were conducted concurrently: one in adults with obesity without diabetes, published in the New England Journal of Medicine in June 2023, and one in adults with type 2 diabetes, published simultaneously in The Lancet
As a reduction of 0.5% in HbA1c is a clinically important difference (Zinman et al., 2018), a greater reduction by liraglutide may contribute to the renoprotective effects
Mounjaro and Zepbound contain a different active ingredient (tirzepatide), and target both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) pathways
